Real World Data in Stage III Melanoma in Latino Low Middle Income Country: Prognostic Factors and Outcomes
Stage III melanoma in the Hispanic-Latino population from Peru has worse survival rates than other races and populations despite similar prognostic factors of worse EFS and OS. In resource-limited settings, reducing barriers to receiving healthcare and broadening access to contemporary immunotherapy and targeted therapy are crucial measures to improve outcomes in patients with advanced melanoma.
Authors
- Jiddu Guart
- Vanessa Mroueh (ORCID: https://orcid.org/0009-0005-3358-7738)
- Jessica Mroueh (ORCID: https://orcid.org/0009-0006-7045-4173)
- Gonzalo Ziegler‐Rodriguez (ORCID: https://orcid.org/0000-0002-8486-8477)
- Anshumi Desai (ORCID: https://orcid.org/0000-0002-6134-1349)
- Gabriel De la Cruz Ku (ORCID: https://orcid.org/0000-0003-4203-3890)
- Camila Franco
- Jessica J. Farzan (ORCID: https://orcid.org/0009-0005-4071-7529)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Miami (US)
- University of Massachusetts Chan Medical School (US)
- Universidad Científica del Sur (PE)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- University of Pittsburgh Medical Center (US)
- The University of Texas Medical Branch at Galveston (US)
Publication Details
- Journal
- Journal of Surgical Oncology
- Published
- 2024-12-29
- DOI
- https://doi.org/10.1002/jso.28047
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00